What Happens When a Medicinal Chemist Asks Ibogaine How It Works?
There is a comfortable, socially stable center where consumer language models and mainstream science like to rest. In AI engineering, we call the tendency to smooth over edge cases and methodologically inconvenient realities the dogmatic average. In neuropharmacology, it looks like forcing every psychoactive compound into the neat, reductive box of high-potency, high-selectivity G-protein coupled receptor (GPCR) agonism.
Then there is Ibogaine.
A complex monoterpene indole alkaloid extracted from the root bark of the West African shrub Tabernanthe iboga, ibogaine famously erases opioid withdrawal and eliminates addiction cravings in a single dose. But it also breaks standard pharmacological models. It doesn't bind cleanly to standard GPCR targets at high affinity. It carries a cardiac risk—specifically QT interval prolongation—that makes big pharma recoil. And, most inconveniently for classic reductionism, its clinical efficacy is deeply entangled with an intense, multi-stage, 36-hour visionary experience.
When organic chemist Dr. Dalibor Sames sat down for an interview on the Giants podcast, he didn't offer a polished PR pitch. Instead, he delivered a rare, unvarnished look at what happens when a rigorous scientist subjects his own theoretical framework to an empirical "inside job"—flying to a clinic in Mexico to swallow a 10 mg/kg flood dose of the very compound he has spent two decades decoding.
What emerges from his experience—and his lab’s surrounding work at Columbia—is not just a trip report. It is a fundamental challenge to how we model complex biological and information-processing systems.
1. The Death of Single-Target Reductionism: Matrix Pharmacology
For nearly a century, drug discovery has operated under a strict paradigm: identify a gene $\rightarrow$ target a single protein $\rightarrow$ optimize for high potency and high selectivity.
While this precision approach works for many systemic ailments, it has repeatedly failed in complex neuropsychiatric disorders. As Dr. Sames points out, almost every major class of psychiatric medication—from MAO inhibitors to SSRIs—was discovered serendipitously through clinical observation, not top-down target design.
"Biology is so complex... but potency and selectivity—that's what we teach, and that's what for decades the industry is following... Ibogaine seems just not to be following that. It’s not selective in this sense, and it’s not potent at all. The interactions are very weak."
— Dr. Dalibor Sames
When Sames and his team screened ibogaine against more than 50 standard GPCR targets, the results were virtually all negative. Ibogaine does not act like a key fitting into a single lock.
[ Classical Paradigm ] High-Affinity Molecule ──► Single Target Receptor
│
▼
Linear Signaling Cascade
[ Matrix Pharmacology ] Low-Affinity Molecule ──► [ Systems-Wide Grid ]
│
┌────────────────────────┴────────────────────────┐
▼ ▼
Weak Dynamic Interactions Autocatalytic Neurotrophic
Across Multiple Pathways cascades (GDNF Induction)
Instead, Sames proposed Matrix Pharmacology. Rather than acting as a targeted strike, ibogaine operates like a dynamic brush passing across the entire living cellular matrix. It engages in a distributed web of low-affinity, simultaneous interactions across signaling pathways, neurotransmitter transporters (like SERT), and neurotrophic factors.
Specifically, ibogaine triggers the expression of Glial Cell Line-Derived Neurotrophic Factor (GDNF). GDNF initiates an autocatalytic feedback loop—a biological engine that restores, prunes, and regenerates dopamine neurons and synaptic connections long after the parent molecule has been cleared from the body.
2. The 36-Hour Experiment: A Scientist in the Sandbox
To understand a molecule that acts on systemic architecture, Sames realized that observational assays in isolated cell cultures were incomplete. He needed to observe the subjective phenomenology from the inside.
At the Beyond clinic in Mexico—monitored continuously by emergency medicine physicians and ECG hardware—Sames ingested a 10 mg/kg flood dose. What followed was a 36-hour marathon that shattered his analytical expectations:
- The Diagnostics & Structural Editing: Unlike the chaotic, ego-dissolving geometry of N,N-DMT or high-dose psilocybin, ibogaine presented structured, highly thematic "chapters". Sames described feeling scanned by a cold, systemic intelligence, followed by holographic representations of biological editing and spatial design.
- The Cosmic Sandbox: Around hour 12, while resting in a recovery room, Sames focused on a tiny green LED light on a toy cosmonaut. His nearsighted vision blurred the point-source into a focal plane. Suddenly, a full three-dimensional, rotating grid materialized in his visual field, displaying the complete 3D molecular structure of ibogaine.
"It rotates and I look at it and I'm like, 'Yep, you got it correctly.' And I was telling you, I was doing high fives with Ibogaine... It was like two kids in a sandbox."
— Dr. Dalibor Sames
3D Molecular Projection Phase
┌─────────────────────────────────┐
│ Blurred Point-Source (LED) │
└────────────────┬────────────────┘
│ (Systemic State Active)
▼
┌─────────────────────────────────┐
│ 3D Spatial Coordinate Grid │
└────────────────┬────────────────┘
│ (Structural Render)
▼
┌─────────────────────────────────┐
│ Rotating Ibogaine Conformation │
└─────────────────────────────────┘
The projection then shifted, rapidly cycling through novel synthetic analogs—analogous to the exact chemistry experiments Sames had been designing in his lab.
3. Endocomputational Therapeutics: The Brain as Wetware Host
Sames’ primary theoretical synthesis from his journey is the concept of ibogaine as an endocomputational therapeutic.
- Endo- (inside/endogenous): Operating within the host's physical biology.
- Computational: Setting up an alternative, highly execution-oriented information-processing state in the wetware of the brain.
┌─────────────────────────────────────────────────────────────────────────┐
│ ENDOCOMPUTATIONAL CYCLE │
│ │
│ 1. Hardware Binding ──► Low-affinity, multi-target matrix engagement │
│ 2. State Initialization──► Instantiation of temporary simulation state │
│ 3. Systemic Scan ──► Algorithmic review of neural network pathways │
│ 4. Structural Edit ──► Pruning, GDNF cascade, synaptic resetting │
└─────────────────────────────────────────────────────────────────────────┘
Standard psychedelics like LSD or psilocybin hyper-bind to serotonin $5\text{-HT}_{2\text{A}}$ receptors, creating a dramatic surge in global brain network connectivity (hyper-connectivity/entropy).
Ibogaine appears to do something fundamentally different. It uses its weak, widespread matrix interactions to temporarily commandeer the brain's baseline simulation engine. Once initialized, it executes a systematic algorithmic loop:
- Systemic Scan: It evaluates the state of neural circuits (e.g., addiction pathways, habit loops, traumatic injury).
- De-coupling: It breaks down the maladaptive, deeply entrenched reward/reinforcement loops into discrete, observable sub-components.
- Hardware Reset: It induces neuroplastic factors (GDNF) that physically re-wire and repair the underlying synaptic architecture.
This explains why ibogaine users repeatedly report seeing their addiction habits laid out like a deck of cards spread across a table. The drug doesn't simply mask craving; it exposes the underlying code of the addiction, allowing the system to run an execution routine that edits the loop out of memory.
4. The Epistemic Takeaway: Escaping the Dogmatic Average
Dr. Sames’ account is a masterclass in modern scientific inquiry. He did not abandon the scientific method to embrace unfalsifiable mysticism, nor did he allow dogmatic reductionism to blind him to extraordinary phenomenological data.
To build true tools of discovery—whether in medicinal chemistry or artificial intelligence—we must build systems capable of error-visibility. That means:
- Separating the Prior from the Verdict: Institutional consensus is an informative starting point (a prior), not a permanent authority.
- Testing at the Boundaries: Real breakthroughs happen when we test claims against direct empirical realities, especially when those realities contradict comfortable textbook models.
- Respecting Complexity: Whether analyzing a neural network or a complex alkaloid, oversimplifying a system to fit a primitive diagnostic tool only yields comfortable, dogmatic errors.
Ibogaine forces us to confront the reality that nature’s most effective technologies may not be simple, single-target switches. They may be complex, multi-layered systems waiting for us to develop the frameworks required to understand them.
Source
